Non-Alcoholic Fatty Liver Disease Trial, Recruiting (NCT05930093)

Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT05930093 Sponsor: TCM Biotech International Corp. Condition: Non-Alcoholic Fatty Liver Disease

Printed from Voxsanity (voxsanity.com.au) — NCT05930093 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Non Alcoholic Fatty Liver Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 20 and 75 years old (male or female)
You are able to give written consent and can communicate clearly with the study team
Your body mass index (BMI) is between 20 and 50, and your weight has been stable for the past 3 months
A special liver scan called a FibroScan shows a certain level of fat in your liver (CAP score of 238 or higher)
The same FibroScan shows your liver scarring is at a low-to-moderate level (F0 to F3) (confirm with trial site)

Who may not be able to join:

You are pregnant, breastfeeding, planning to become pregnant, or not willing to use an acceptable form of birth control during the study
You have Type 1 diabetes
You have been diagnosed with another cause of chronic liver disease, such as hepatitis B or C, autoimmune liver disease, or certain inherited conditions affecting the liver
You currently take certain medications that can cause fat buildup in the liver, such as amiodarone, methotrexate, tamoxifen, high-dose steroids, or certain hormonal therapies (confirm with trial site)
You currently take high-dose vitamin E, pioglitazone, certain diabetes medications (SGLT2 inhibitors or GLP-1 agonists), or any approved drug for fatty liver disease
You have had a serious health event in the past 6 months, such as heart failure, a stroke, a mini-stroke, unstable heart disease, severe lung disease, kidney failure requiring dialysis, or an organ transplant
You drink more alcohol than the study allows (more than 20g per day for women or 30g per day for men), or you have a history of alcohol misuse (confirm with trial site)
Certain abnormal blood test results, including high triglycerides, abnormal liver enzymes, or problems with blood clotting or protein levels (confirm with trial site)
Your blood sugar control (HbA1c) has been poor, above 8.5%, in the past 3 months
You are planning to have major surgery during the study, such as weight-loss surgery or bile duct surgery
You have taken part in another clinical trial within the past 30 days
You have a history of HIV

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +886-2-23123456

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05930093

Sponsor: TCM Biotech International Corp.

Phase: Not Applicable

Status: Recruiting

Condition: Non-Alcoholic Fatty Liver Disease

Trial contact: +886-2-23123456

More information: https://clinicaltrials.gov/study/NCT05930093

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 20 and 75 years old (male or female)
You are able to give written consent and can communicate clearly with the study team
Your body mass index (BMI) is between 20 and 50, and your weight has been stable for the past 3 months
A special liver scan called a FibroScan shows a certain level of fat in your liver (CAP score of 238 or higher)
The same FibroScan shows your liver scarring is at a low-to-moderate level (F0 to F3) (confirm with trial site)

Who may not be able to join:

You are pregnant, breastfeeding, planning to become pregnant, or not willing to use an acceptable form of birth control during the study
You have Type 1 diabetes
You have been diagnosed with another cause of chronic liver disease, such as hepatitis B or C, autoimmune liver disease, or certain inherited conditions affecting the liver
You currently take certain medications that can cause fat buildup in the liver, such as amiodarone, methotrexate, tamoxifen, high-dose steroids, or certain hormonal therapies (confirm with trial site)
You currently take high-dose vitamin E, pioglitazone, certain diabetes medications (SGLT2 inhibitors or GLP-1 agonists), or any approved drug for fatty liver disease
You have had a serious health event in the past 6 months, such as heart failure, a stroke, a mini-stroke, unstable heart disease, severe lung disease, kidney failure requiring dialysis, or an organ transplant
You drink more alcohol than the study allows (more than 20g per day for women or 30g per day for men), or you have a history of alcohol misuse (confirm with trial site)
Certain abnormal blood test results, including high triglycerides, abnormal liver enzymes, or problems with blood clotting or protein levels (confirm with trial site)
Your blood sugar control (HbA1c) has been poor, above 8.5%, in the past 3 months
You are planning to have major surgery during the study, such as weight-loss surgery or bile duct surgery
You have taken part in another clinical trial within the past 30 days
You have a history of HIV

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

TCM Biotech International Corp.

Registry

ClinicalTrials.gov

Start date

7 December 2023

Est. completion

1 January 2026

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

Reduction of Liver Fat

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov